drugset / Trial / NCT03366064

Haploidentical NK Cells After Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

NCT03366064

NaSingle-groupOpen-labelTreatment

Summary

This phase 1 trial investigate safety and maximum tolerated dose of natural killer (NK) cells derived from haploidentical family donors in patients with non-small cell lung cancer

Timeline

Start
2017-11-09
Primary completion
2018-09-03
Completion
2019-06-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject donor-derived NK cells Cell therapy 1.25e+09 cells Intravenous
Subject donor-derived NK cells Cell therapy 2.5e+09 cells Intravenous
Subject donor-derived NK cells Cell therapy 5e+09 cells Intravenous
Background Pemetrexed Small molecule 500 mg/m2 Intravenous